New MRI dye could reveal hidden brain artery inflammation

NCT ID NCT03084523

Completed Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study tested whether a special MRI contrast agent called ferumoxytol can detect inflammation in brain arteries of people who recently had a stroke. Researchers compared it to standard gadolinium contrast in 30 participants with narrowed brain arteries. The goal was to see if ferumoxytol highlights inflamed areas better, which could help prevent future strokes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ferumoxytol (Feraheme) injectable MRI contrast agent
What this could lead to: If successful, this could lead to better imaging methods to identify inflamed brain arteries, potentially improving stroke prevention strategies.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply broadly. The new contrast agent may not show inflammation better than standard methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRACRANIAL ATHEROSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebral atherosclerosis intracranial arteriosclerosis ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRACRANIAL ATHEROSCLEROSIS STROKE

Contacts and locations

Locations

Yale University

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.